JPS62215520A - Adhesive gel composition - Google Patents
Adhesive gel compositionInfo
- Publication number
- JPS62215520A JPS62215520A JP60234257A JP23425785A JPS62215520A JP S62215520 A JPS62215520 A JP S62215520A JP 60234257 A JP60234257 A JP 60234257A JP 23425785 A JP23425785 A JP 23425785A JP S62215520 A JPS62215520 A JP S62215520A
- Authority
- JP
- Japan
- Prior art keywords
- polyvinyl alcohol
- pva
- gel composition
- composition
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 42
- 230000001070 adhesive effect Effects 0.000 title claims abstract description 22
- 239000000853 adhesive Substances 0.000 title claims abstract description 19
- 239000004372 Polyvinyl alcohol Substances 0.000 claims abstract description 55
- 229920002451 polyvinyl alcohol Polymers 0.000 claims abstract description 55
- 238000007127 saponification reaction Methods 0.000 claims abstract description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 13
- 238000006116 polymerization reaction Methods 0.000 claims abstract description 11
- 239000002390 adhesive tape Substances 0.000 abstract description 3
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 3
- 239000003795 chemical substances by application Substances 0.000 abstract description 2
- 238000001816 cooling Methods 0.000 abstract description 2
- 239000011505 plaster Substances 0.000 abstract description 2
- 239000000730 antalgic agent Substances 0.000 abstract 1
- 239000002260 anti-inflammatory agent Substances 0.000 abstract 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 38
- 239000000499 gel Substances 0.000 description 28
- -1 if necessary Substances 0.000 description 10
- 230000000052 comparative effect Effects 0.000 description 5
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000000017 hydrogel Substances 0.000 description 4
- 150000005846 sugar alcohols Polymers 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 3
- 238000001879 gelation Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 229920003169 water-soluble polymer Polymers 0.000 description 3
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- CUFNKYGDVFVPHO-UHFFFAOYSA-N azulene Chemical compound C1=CC=CC2=CC=CC2=C1 CUFNKYGDVFVPHO-UHFFFAOYSA-N 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- SEEPANYCNGTZFQ-UHFFFAOYSA-N sulfadiazine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CC=N1 SEEPANYCNGTZFQ-UHFFFAOYSA-N 0.000 description 2
- 229960004306 sulfadiazine Drugs 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 description 1
- FMCGSUUBYTWNDP-ONGXEEELSA-N (1R,2S)-2-(dimethylamino)-1-phenyl-1-propanol Chemical compound CN(C)[C@@H](C)[C@H](O)C1=CC=CC=C1 FMCGSUUBYTWNDP-ONGXEEELSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000157282 Aesculus Species 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 235000002566 Capsicum Nutrition 0.000 description 1
- 240000008574 Capsicum frutescens Species 0.000 description 1
- 229920000298 Cellophane Polymers 0.000 description 1
- GXGJIOMUZAGVEH-UHFFFAOYSA-N Chamazulene Chemical compound CCC1=CC=C(C)C2=CC=C(C)C2=C1 GXGJIOMUZAGVEH-UHFFFAOYSA-N 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- OJMMVQQUTAEWLP-UHFFFAOYSA-N Lincomycin Natural products CN1CC(CCC)CC1C(=O)NC(C(C)O)C1C(O)C(O)C(O)C(SC)O1 OJMMVQQUTAEWLP-UHFFFAOYSA-N 0.000 description 1
- 244000280244 Luffa acutangula Species 0.000 description 1
- 235000009814 Luffa aegyptiaca Nutrition 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- FMCGSUUBYTWNDP-UHFFFAOYSA-N N-Methylephedrine Natural products CN(C)C(C)C(O)C1=CC=CC=C1 FMCGSUUBYTWNDP-UHFFFAOYSA-N 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- 108010087702 Penicillinase Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000920652 Quercus lusitanica Species 0.000 description 1
- 229920000297 Rayon Polymers 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 208000033809 Suppuration Diseases 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- BZHJMEDXRYGGRV-UHFFFAOYSA-N Vinyl chloride Chemical compound ClC=C BZHJMEDXRYGGRV-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 229940069521 aloe extract Drugs 0.000 description 1
- 229960002213 alprenolol Drugs 0.000 description 1
- PAZJSJFMUHDSTF-UHFFFAOYSA-N alprenolol Chemical compound CC(C)NCC(O)COC1=CC=CC=C1CC=C PAZJSJFMUHDSTF-UHFFFAOYSA-N 0.000 description 1
- 230000001760 anti-analgesic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940127088 antihypertensive drug Drugs 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 239000000168 bronchodilator agent Substances 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 239000001390 capsicum minimum Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- CZTQZXZIADLWOZ-CRAIPNDOSA-N cefaloridine Chemical compound O=C([C@@H](NC(=O)CC=1SC=CC=1)[C@H]1SC2)N1C(C(=O)[O-])=C2C[N+]1=CC=CC=C1 CZTQZXZIADLWOZ-CRAIPNDOSA-N 0.000 description 1
- 229960003866 cefaloridine Drugs 0.000 description 1
- SXPWTBGAZSPLHA-UHFFFAOYSA-M cetalkonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 SXPWTBGAZSPLHA-UHFFFAOYSA-M 0.000 description 1
- 229960000228 cetalkonium chloride Drugs 0.000 description 1
- PMRJYBALQVLLSJ-UHFFFAOYSA-N chamazulene Natural products CCC1=CC2=C(C)CCC2=CC=C1 PMRJYBALQVLLSJ-UHFFFAOYSA-N 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 229960002896 clonidine Drugs 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- ALEXXDVDDISNDU-JZYPGELDSA-N cortisol 21-acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O ALEXXDVDDISNDU-JZYPGELDSA-N 0.000 description 1
- 229960000265 cromoglicic acid Drugs 0.000 description 1
- IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 229960000520 diphenhydramine Drugs 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- HQQADJVZYDDRJT-UHFFFAOYSA-N ethene;prop-1-ene Chemical group C=C.CC=C HQQADJVZYDDRJT-UHFFFAOYSA-N 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- PGBHMTALBVVCIT-VCIWKGPPSA-N framycetin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO PGBHMTALBVVCIT-VCIWKGPPSA-N 0.000 description 1
- FODTZLFLDFKIQH-FSVGXZBPSA-N gamma-Oryzanol (TN) Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)O[C@@H]2C([C@@H]3CC[C@H]4[C@]5(C)CC[C@@H]([C@@]5(C)CC[C@@]54C[C@@]53CC2)[C@H](C)CCC=C(C)C)(C)C)=C1 FODTZLFLDFKIQH-FSVGXZBPSA-N 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- ACGUYXCXAPNIKK-UHFFFAOYSA-N hexachlorophene Chemical compound OC1=C(Cl)C=C(Cl)C(Cl)=C1CC1=C(O)C(Cl)=CC(Cl)=C1Cl ACGUYXCXAPNIKK-UHFFFAOYSA-N 0.000 description 1
- 229960004068 hexachlorophene Drugs 0.000 description 1
- 235000010181 horse chestnut Nutrition 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 229960001067 hydrocortisone acetate Drugs 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000011256 inorganic filler Substances 0.000 description 1
- 229910003475 inorganic filler Inorganic materials 0.000 description 1
- MOYKHGMNXAOIAT-JGWLITMVSA-N isosorbide dinitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O[N+](=O)[O-])CO[C@@H]21 MOYKHGMNXAOIAT-JGWLITMVSA-N 0.000 description 1
- 229960000201 isosorbide dinitrate Drugs 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 238000010030 laminating Methods 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 229960005287 lincomycin Drugs 0.000 description 1
- OJMMVQQUTAEWLP-KIDUDLJLSA-N lincomycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 OJMMVQQUTAEWLP-KIDUDLJLSA-N 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229940102728 methylbenzethonium Drugs 0.000 description 1
- 229960002221 methylephedrine Drugs 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- OIXVKQDWLFHVGR-WQDIDPJDSA-N neomycin B sulfate Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO OIXVKQDWLFHVGR-WQDIDPJDSA-N 0.000 description 1
- 229940053050 neomycin sulfate Drugs 0.000 description 1
- 229960001597 nifedipine Drugs 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 239000004745 nonwoven fabric Substances 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229940056360 penicillin g Drugs 0.000 description 1
- 229950009506 penicillinase Drugs 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 229960002508 pindolol Drugs 0.000 description 1
- PHUTUTUABXHXLW-UHFFFAOYSA-N pindolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=NC=C[C]12 PHUTUTUABXHXLW-UHFFFAOYSA-N 0.000 description 1
- 239000002985 plastic film Substances 0.000 description 1
- 229920006255 plastic film Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000002964 rayon Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229960002052 salbutamol Drugs 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 150000003902 salicylic acid esters Chemical class 0.000 description 1
- LMEWRZSPCQHBOB-UHFFFAOYSA-M silver;2-hydroxypropanoate Chemical compound [Ag+].CC(O)C([O-])=O LMEWRZSPCQHBOB-UHFFFAOYSA-M 0.000 description 1
- 239000004328 sodium tetraborate Substances 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 229960000195 terbutaline Drugs 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940072358 xylocaine Drugs 0.000 description 1
Landscapes
- Materials For Medical Uses (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
【発明の詳細な説明】
〔産業上の利用分野〕
この発明は、消炎、鎮痛用パップ剤、冷却用具等の含水
貼付剤の基剤として用いられる粘着性に優れたゲル組成
物に関するものである。[Detailed Description of the Invention] [Industrial Application Field] This invention relates to a gel composition with excellent adhesiveness that is used as a base for water-containing patches for anti-inflammatory and analgesic poultices, cooling devices, etc. .
現在、含水ゲル組成物は、ポリビニルアルコール、ポリ
アクリル酸あるいはポリアクリル酸塩等の水溶性高分子
を利用して作製されており、その特徴として肌ざわりが
良好で、生体への刺激も少ないこと(桜田洋、“高分子
″24. 590 (1975)、丹沢宏、“医用高分
子”P2O,PO2(1978)井守出版)、親水性で
生体組織と類似していること(丹沢宏、“医用高分子”
P2O(1978)あるいは選択的透過性にも優れてい
ること等があげられ医用材料や医薬徐放化材料として期
待されている。Currently, water-containing gel compositions are made using water-soluble polymers such as polyvinyl alcohol, polyacrylic acid, or polyacrylates, and their characteristics are that they feel good on the skin and are less irritating to living organisms ( Hiroshi Sakurada, “Polymers” 24. 590 (1975), Hiroshi Tanzawa, “Medical Polymers” P2O, PO2 (1978) Imori Publishing), hydrophilicity and resemblance to biological tissue (Hiroshi Tanzawa, “Medical Polymers” P2O, PO2 (1978) Imori Publishing); molecule"
It is expected to be used as a medical material or a drug sustained release material because of its excellent P2O (1978) or selective permeability.
このうち、ポリビニルアルコール(以下「PvA」と略
す)を利用した含水ゲル組成物は、古くから種々報告さ
れており、また近年、強度的に優れたPVA系含水ゲル
組成物が報告されている。Among these, various hydrogel compositions using polyvinyl alcohol (hereinafter abbreviated as "PvA") have been reported for a long time, and in recent years, PVA-based hydrogel compositions with excellent strength have been reported.
しかしながら、従来のPVA系含水ゲル組成物は、いず
れも皮膚に対する粘着性を有していす、上記ゲル組成物
を創傷治療剤や湿布用保冷剤として皮膚表面に用いる場
合、それ自体では皮膚に装着することができないため、
粘着テープ等を用いて皮膚表面に固定しなければならず
、使い勝手のよくないものである。However, all conventional PVA-based hydrogel compositions have adhesiveness to the skin. Because it is not possible to
It must be fixed to the skin surface using adhesive tape or the like, making it inconvenient to use.
この発明は、このような事情に鑑みなされたもので、保
形状性に冨み、かつ保水性および貼着性に優れ、しかも
直接皮膚表面に固定しうる粘着性を有するゲル組成物を
提供することを目的とする。The present invention was made in view of the above circumstances, and provides a gel composition that is rich in shape retention, has excellent water retention and adhesive properties, and has adhesive properties that can be directly fixed to the skin surface. The purpose is to
上記の目的を達成するため、この発明の粘着性ゲル組成
物は、ポリビニルアルコールと水とを主要成分とする粘
着性ゲル組成物であって、上記ポリビニルアルコールが
完全けん北壁ポリビニルアルコールと部分けん北壁ポリ
ビニルアルコールからなるという構成をとる。In order to achieve the above object, the adhesive gel composition of the present invention is an adhesive gel composition containing polyvinyl alcohol and water as main components, in which the polyvinyl alcohol completely binds, the north wall polyvinyl alcohol partially binds, The north wall is made of polyvinyl alcohol.
すなわち、本発明者らは、皮膚に貼付するのに適した粘
着性ゲル組成物を得るべく鋭意研究を重ねた結果、PV
Aとして完全けん化型PVAと部分けん化型PVAとを
併用すると所期の目的を達成し得ることを見いだし、こ
の発明に到達したのである。That is, as a result of intensive research to obtain an adhesive gel composition suitable for application to the skin, the present inventors discovered that PV
They discovered that the desired objective could be achieved by using fully saponified PVA and partially saponified PVA in combination as A, and arrived at this invention.
この発明の粘着性ゲル組成物は、PVAと水とをその主
要成分とするもので、特にPVAとして、完全けん化型
PVAと部分けん化型PVAとを併用するものである。The adhesive gel composition of the present invention has PVA and water as its main components, and in particular, as PVA, fully saponified PVA and partially saponified PVA are used in combination.
ここで、主要成分とするとは、全体が主要成分のみから
なる場合も含める趣旨である。Here, the term "main component" is intended to include cases where the entire component consists only of the main component.
上記PVAは、公知の方法、例えばポリ酢酸ビニルをア
ルカリ等でけん化することにより得られる水溶性高分子
化合物で、ゲル状態で組成物の骨格を形成し、生体親和
性が良好で皮膚に貼付するのに適している。上記PVA
のけん化度、平均重合度あるいは組成物中での配合比率
を変化させることにより容易に組成物の機械的強度を変
えることができるが、この発明に用いるPVAは、完全
けん化型PVAと部分けん化型PVAの双方である。The above-mentioned PVA is a water-soluble polymer compound obtained by a known method, for example, by saponifying polyvinyl acetate with an alkali, etc. It forms the skeleton of the composition in a gel state, has good biocompatibility, and can be applied to the skin. suitable for. Above PVA
The mechanical strength of the composition can be easily changed by changing the degree of saponification, the average degree of polymerization, or the blending ratio in the composition. Both PVA.
一般に、けん化度96.0モル%のPVAが完全けん化
型、80〜93.5モル%のPVAが部分けん化型と呼
ばれているが、この発明において、完全けん化型PVA
とは、けん化度が95モル%以上のもののことである。Generally, PVA with a saponification degree of 96.0 mol% is called a completely saponified type, and PVA with a saponification degree of 80 to 93.5 mol% is called a partially saponified type.
"Saponification degree is 95 mol% or more."
この完全けん化型PVAは、この発明のゲル組成物の骨
格を形成するものであり、生体親和性が良好で、皮膚貼
付に適した特性を備えている。この観点から、けん化度
が95モル%以上と設定されたのであり、このけん化度
を有していれば、この発明を達成しうる。より好適なの
は99モル%以上である。けん化度が95モル%未満の
ものでは充分なゲル化が得られずゲルの骨格を形成しえ
ない。This completely saponified PVA forms the skeleton of the gel composition of the present invention, and has good biocompatibility and properties suitable for application to the skin. From this point of view, the degree of saponification was set to be 95 mol% or more, and this invention can be achieved with this degree of saponification. More preferred is 99 mol% or more. If the degree of saponification is less than 95 mol%, sufficient gelation cannot be obtained and a gel skeleton cannot be formed.
上記完全けん化型PVAの平均重合度は500以上、好
ましくは1000以上、さらに好ましくは1500〜2
000に設定することが望ましい。すなわち、平均重合
度が500未満では充分なゲル化が得られないからであ
る。The average degree of polymerization of the completely saponified PVA is 500 or more, preferably 1000 or more, more preferably 1500-2
It is desirable to set it to 000. That is, if the average degree of polymerization is less than 500, sufficient gelation cannot be obtained.
また、上記部分けん化型PVAは、けん化度85モル%
以上93.5モル%以下のもののことであり、このもの
は、ゲル組成物に、皮膚貼付しうるよう粘着性を付与す
る。特に好適なのは、けん化度が88モル%以上93.
5モル%以下のものである。すなわち、85モル%未満
のものを使用すると、得られるゲル組成物にべとつきが
増加して皮膚貼付に不適となり、逆に93.5モル%を
超えるものを使用すると得られるゲル組成物に粘着性が
認められなくなるからである。In addition, the above partially saponified PVA has a saponification degree of 85 mol%.
This refers to 93.5 mol% or less of the above, and this substance imparts tackiness to the gel composition so that it can be applied to the skin. Particularly preferred is a degree of saponification of 88 mol% or more, 93.
It is 5 mol% or less. That is, if less than 85 mol% is used, the resulting gel composition will have increased stickiness, making it unsuitable for skin application; on the other hand, if more than 93.5 mol% is used, the resulting gel composition will become sticky. This is because it will no longer be recognized.
上記部分けん北壁PVAは、平均重合度が200以上、
好ましくは1000〜3000に設定することが望まし
い。すなわち、平均重合度が200未満のものを使用す
ると皮膚貼付に適した粘着性が得られなくなるからであ
る。The above-mentioned partial north wall PVA has an average degree of polymerization of 200 or more,
It is desirable to set it preferably between 1000 and 3000. That is, if a material having an average degree of polymerization of less than 200 is used, adhesiveness suitable for application to the skin cannot be obtained.
上記2種類のPVAと共に用いられる水としては、特に
限定するものではなく、通常、含水ゲルの製造に使用さ
れる水を用いることができる。The water used together with the above two types of PVA is not particularly limited, and water that is normally used for producing hydrogels can be used.
なお、この発明の粘着性ゲル組成物には、必要に応じて
上記の原料とともに多価アルコールを用いることができ
、また創傷皮膚の雑菌感染防止ないしは化膿側の化学治
療法の点から抗菌薬を用いることもできる。場合によっ
ては、経皮適用が可能な生理活性物質も用いることがで
きる。In addition, polyhydric alcohol can be used in the adhesive gel composition of the present invention in addition to the above-mentioned raw materials, if necessary, and antibacterial agents can be used to prevent bacterial infection of the wound skin or to treat suppuration. It can also be used. In some cases, physiologically active substances that can be applied transdermally can also be used.
上記多価アルコールとしては、グリセリン、ポリグリセ
リン、エチレングリコール、ジエチレングリコール、ポ
リエチレングリコール、プロピレングリコール、ジプロ
ピレングリコール、ポリプロピレングリコール、エチレ
ン−プロピレングリコール共重合体等があげられる。こ
れらの多価アルコールは、単独で用いてもよいし、二種
以上を用いても支障はない。Examples of the polyhydric alcohol include glycerin, polyglycerin, ethylene glycol, diethylene glycol, polyethylene glycol, propylene glycol, dipropylene glycol, polypropylene glycol, and ethylene-propylene glycol copolymer. These polyhydric alcohols may be used alone or in combination of two or more without any problem.
また、抗菌薬としては、サルファジアジン、恨サルファ
ジアジン、ベンザルコニウムクロリド。Antibiotics include sulfadiazine, sulfadiazine, and benzalkonium chloride.
セタルコニウムクロリド、メチルベンゼトニウム、硫酸
ネオマイシン、ヘキサクロロフェン、エオシン、ペニシ
リンG、セファロシン、セファロリジン、テトラサイク
リン、リンコマイシン、ナイスクチン、カナマイシン、
ペニシリナーゼ抵抗性ペニシリン、硫酸フラジオマイシ
ン、乳酸銀等があげられ、単独でもしくは併せて使用さ
れる。Cetalkonium chloride, methylbenzethonium, neomycin sulfate, hexachlorophene, eosin, penicillin G, cephalocin, cephaloridine, tetracycline, lincomycin, nyscutin, kanamycin,
Examples include penicillinase-resistant penicillin, fradiomycin sulfate, silver lactate, and the like, which are used alone or in combination.
上記生理活性物質としては、例えば、サリチル酸エステ
ル、メントール、カンファー、ハツカ。Examples of the physiologically active substances include salicylic acid ester, menthol, camphor, and peppermint.
トウガラチェキス。カブサイシン等のパップ剤用薬剤、
プレゾニゾロン、デキサメタシン、ヒドロコルチゾン、
酢酸デキサメタシン、酢酸ヒドロコルチゾン等のステロ
イド、ニトログリセリン、イソソルビドジニトレート等
の狭心症薬、ペンシカイン、プロ力イン、キシロカイン
等の局所麻酔剤、ジフェンヒドラミン等の抗ヒスタミン
剤、アルプレノロール、プロプラノロール、ピンドロー
ル等のβ−遮断薬、クロニジン、ニフェジピン等の血圧
降下剤、メチルエフェドリン、クロルブレナリン、サル
ブタモール、テルブタリン等の気管支拡張薬、クロモグ
リク酸等の喘息薬、プロスタグランジン、ホルモン剤等
の薬剤、水溶性コラーゲン、アロエエキス、女性ホルモ
ン、ヘチマエキス等の美肌成分、アラントイン、レシチ
ン、ビタミンE、A、D、B、、パントテン酸等のビタ
ミン類、カムアズレン、グアヤアズレン、γ−オリザノ
ール、尿素、イオウ、サリチル酸、黄柏、西洋トチツキ
、当帰、紫根等の生薬エキス、香料等があげられる。こ
れらは単独で用いてもよいし併用しても支障はない。Capsicum Chekis. Poultice agents such as cabsaicin,
prezonisolone, dexamethacin, hydrocortisone,
Steroids such as dexamethacin acetate and hydrocortisone acetate, anginal drugs such as nitroglycerin and isosorbide dinitrate, local anesthetics such as pensicaine, protylene, and xylocaine, antihistamines such as diphenhydramine, and β-stimulants such as alprenolol, propranolol, and pindolol. - Blockers, antihypertensive drugs such as clonidine and nifedipine, bronchodilators such as methylephedrine, chlorbrenalin, salbutamol, and terbutaline, asthma drugs such as cromoglycic acid, drugs such as prostaglandins and hormones, water-soluble collagen, and aloe extract. , female hormones, beautifying ingredients such as loofah extract, allantoin, lecithin, vitamins E, A, D, B, vitamins such as pantothenic acid, cam azulene, guaya azulene, γ-oryzanol, urea, sulfur, salicylic acid, yellow oak, western horse chestnut Examples include extracts of herbal medicines such as , Toki, Shikon, etc., and fragrances. These may be used alone or in combination without any problem.
この発明の粘着性ゲル組成物は、例えばつぎのようにし
て製造することができる。すなわち、−5℃以下の温度
で、完全けん北壁PVAと部分けん北壁PVAを溶解し
た水溶液を5時間以上凍結し、ついで、0〜10℃の比
較的低温で10時間以上放置してゲル化させることによ
り製造することができる。The adhesive gel composition of the present invention can be produced, for example, as follows. That is, an aqueous solution containing completely embossed north wall PVA and partially embossed north wall PVA is frozen at a temperature below -5°C for 5 hours or more, and then left at a relatively low temperature of 0 to 10°C for 10 hours or more to form a gel. It can be manufactured by
上記完全けん北壁PVAの配合量は、全体の7〜30重
量%(以下「%」と略す)が好ましく、より好ましくは
10〜20%である。すなわち、7%未満ではゲル化が
良好でなく、逆に30%を超えるとゲルの弾性が低下し
、皮膚接着性に乏しくなるからである。The blending amount of the above-mentioned completely broken north wall PVA is preferably 7 to 30% by weight (hereinafter abbreviated as "%"), more preferably 10 to 20%. That is, if it is less than 7%, gelation will not be good, and if it exceeds 30%, the elasticity of the gel will decrease and skin adhesion will be poor.
また、上記部分けん北壁PVAの配合量は、全体の5〜
30%が好ましく、より好ましくは7〜20%である。In addition, the blending amount of PVA on the north wall of the above part is 5 to 50% of the total amount.
It is preferably 30%, more preferably 7 to 20%.
これも上記と同じ理由による。This is also for the same reason as above.
なお、上記2種類のPVAを溶解した水溶液には、必要
に応じて前記多価アルコールや生理活性物質を添加する
ことができる。Note that the polyhydric alcohol and physiologically active substance can be added to the aqueous solution in which the two types of PVA are dissolved, if necessary.
このようにして、この発明の粘着性ゲル組成物が得られ
る。この組成物は、機械的強度、粘着性に優れ1、皮膚
貼付に適しているため、そのまま局所保冷剤、パップ剤
膏体、生体電極用ゲルとして応用できる。また、この組
成物は、いかなる形状にも成形可能で、特に皮膚に適用
するパップ剤等の貼付剤として用いられる場合には、−
軸もしくは二軸押出機等を用いシート状に成形すること
が好ましい。In this way, the adhesive gel composition of this invention is obtained. This composition has excellent mechanical strength and adhesiveness 1 and is suitable for application to the skin, so it can be used as it is as a topical ice pack, poultice plaster, or bioelectrode gel. In addition, this composition can be molded into any shape, and especially when used as a patch such as a poultice applied to the skin, -
It is preferable to form it into a sheet using a shaft or twin-screw extruder.
なお、この発明の粘着性ゲル組成物は、支持体と貼り合
わせることによりパップ剤等として製品化することがで
きる。上記支持体としては、例えば、ポリエチレン、エ
チレン−酢酸ビニル共重合体、塩化ビニル、ポリウレタ
ン、ポリエステル等のプラスチックフィルム、ナイロン
、レイヨン。The adhesive gel composition of the present invention can be commercialized as a poultice or the like by laminating it with a support. Examples of the support include plastic films such as polyethylene, ethylene-vinyl acetate copolymer, vinyl chloride, polyurethane, and polyester, nylon, and rayon.
ウレタン、ポリエステル、脱脂綿等の不織布、布、伸縮
性布、紙、セロファン等があげられ、その用途に応じて
適宜に選択することができる。Examples include nonwoven fabrics such as urethane, polyester, and absorbent cotton, cloth, elastic fabrics, paper, cellophane, and the like, and can be appropriately selected depending on the intended use.
また、この発明の粘着性ゲル組成物を用いた基剤には、
さらに他の水溶性高分子、吸水性樹脂。In addition, the base using the adhesive gel composition of this invention includes:
Furthermore, other water-soluble polymers and water-absorbing resins.
無機質充填剤、粘着付与剤、 pH調節剤、界面活性剤
、キレート剤、各種架橋剤、経皮吸収促進剤。Inorganic fillers, tackifiers, pH regulators, surfactants, chelating agents, various crosslinking agents, transdermal absorption enhancers.
防腐剤等のその他の添加剤を目的に応じて適宜に配合す
ることができる。Other additives such as preservatives can be added as appropriate depending on the purpose.
以上のように、この発明の粘着性ゲル組成物は、完全け
ん化型PVAと部分けん化型PVAと水とを含有してい
るため、ゲルの骨格が強靭で優れた保形性、保水性を有
しており、しかも極めて粘着性に優れているため、従来
のもののように粘着テープ等を用いて皮膚に固定する必
要がなく、極めて取扱いの簡便な、優れた貼付剤となり
うるのである。これがこの発明の最大の特徴である。し
たがって、この発明の粘着性ゲル組成物は、局所保冷剤
、パップ剤膏体、生体電極用ゲル等として幅広く応用す
ることができるのである。As described above, since the adhesive gel composition of the present invention contains fully saponified PVA, partially saponified PVA, and water, the gel skeleton is strong and has excellent shape retention and water retention. Moreover, since it has extremely good adhesive properties, it does not need to be fixed to the skin using adhesive tape or the like as in conventional products, making it an excellent patch that is extremely easy to handle. This is the greatest feature of this invention. Therefore, the adhesive gel composition of the present invention can be widely applied as a local cold pack, a poultice, a bioelectrode gel, etc.
つぎに、実施例について比較例と併せて説明する。Next, examples will be described together with comparative examples.
〔実施例1〜16.比較例1〜4〕
後記の第1表に示す配合で、完全けん化型PVAと部分
けん化型PVAと水の混合溶液を調製し、厚み1龍X
3 (J X 3 aaの容器に入れて一20℃のフリ
ーザ中で12時間凍結した。ついで、これを5℃の恒温
槽中約10時間静置して解凍し、この発明の粘着性ゲル
組成物を得た。[Examples 1 to 16. Comparative Examples 1 to 4] A mixed solution of fully saponified PVA, partially saponified PVA, and water was prepared with the formulation shown in Table 1 below, and the solution was
3 (J. I got something.
また、比較別品として、完全けん化型PVAまたは部分
けん化型PVAの一方だけを含有するをゲル組成物を上
記実施別品と同様の方法で得た。In addition, as a comparative product, a gel composition containing only either fully saponified PVA or partially saponified PVA was obtained in the same manner as the above-mentioned experimental product.
このようにして得られた実施別品と比較別品について、
パネル10名の手の甲に厚みl龍X3C11X3cIm
のサンプルを貼付し、8時間後のサンプルと皮膚との接
着面積率を調べた。この結果を第1表に併せて示す。Regarding the actual product and comparative product obtained in this way,
The thickness of the back of the hand of the 10 panelists is lyu X3C11X3cIm.
A sample was applied to the skin, and the adhesion area ratio between the sample and the skin was examined after 8 hours. The results are also shown in Table 1.
(以下余白)
上記の表から明らかなように、比較例はいずれもゲルと
して得ることができないか、またはゲル化してもサンプ
ルが皮膚に接着せず脱落しているのに対し、実施例は優
れた皮膚接着性を有していることがわかる。(Left below) As is clear from the table above, in all of the comparative examples, either the gel could not be obtained, or even if it gelled, the sample did not adhere to the skin and fell off, whereas the example was excellent. It can be seen that it has good skin adhesion.
〔実施例17〕
けん化度99.5モル%、平均重合度1700の完全け
ん化型PVA15%、けん化度88モル%、平均重合度
1900の部分けん化型PVAl0%、水74.55%
(7)P VA水溶液にホウ砂0.45%加えゲル化さ
せ、この発明のゲル組成物を得た、この組成物について
も前記と同様の皮膚接着力試験を行ったところ、サンプ
ルと皮膚との接着面積率は約70%で、優れた皮膚接着
性を有していることがわかった。[Example 17] 15% fully saponified PVA with a saponification degree of 99.5 mol% and an average degree of polymerization of 1700, 0% partially saponified PVAl with a saponification degree of 88 mol% and an average degree of polymerization of 1900, and 74.55% water.
(7) A gel composition of the present invention was obtained by adding 0.45% borax to a PVA aqueous solution and gelling it. When this composition was also subjected to the same skin adhesion test as described above, the bond between the sample and the skin was The adhesion area ratio was approximately 70%, indicating that it had excellent skin adhesion.
Claims (1)
ゲル組成物であつて、上記ポリビニルアルコールが完全
けん化型ポリビニルアルコールと部分けん化型ポリビニ
ルアルコールからなることを特徴とする粘着性ゲル組成
物。 (2)完全けん化型ポリビニルアルコールの含有量が、
7〜30重量%に設定され、部分けん化型ポリビニルア
ルコールの含有量が、5〜30重量%に設定されている
特許請求の範囲第1項記載の粘着性ゲル組成物。 (3)完全けん化型ポリビニルアルコールが、けん化度
95モル%以上に設定されている特許請求の範囲第1項
または第2項記載の粘着性ゲル組成物。 (4)完全けん化型ポリビニルアルコールが、平均重合
度500以上に設定されている特許請求の範囲第1項〜
第3項のいずれかに記載の粘着性ゲル組成物。 (5)部分けん化型ポリビニルアルコールが、けん化度
85モル%以上に設定されている特許請求の範囲第1項
〜第4項のいずれかに記載の粘着性ゲル組成物。 (6)部分けん化型ポリビニルアルコールが、平均重合
度200以上に設定されている特許請求の範囲第1項〜
第5項のいずれかに記載の粘着性ゲル組成物。[Scope of Claims] 1) An adhesive gel composition containing polyvinyl alcohol and water as main components, wherein the polyvinyl alcohol is composed of fully saponified polyvinyl alcohol and partially saponified polyvinyl alcohol. Gel composition. (2) The content of fully saponified polyvinyl alcohol is
The adhesive gel composition according to claim 1, wherein the content of partially saponified polyvinyl alcohol is set to 7 to 30% by weight, and the content of partially saponified polyvinyl alcohol is set to 5 to 30% by weight. (3) The adhesive gel composition according to claim 1 or 2, wherein the completely saponified polyvinyl alcohol has a saponification degree of 95 mol% or more. (4) The fully saponified polyvinyl alcohol has an average degree of polymerization of 500 or more.
The adhesive gel composition according to any one of Item 3. (5) The adhesive gel composition according to any one of claims 1 to 4, wherein the partially saponified polyvinyl alcohol has a saponification degree of 85 mol% or more. (6) Partially saponified polyvinyl alcohol has an average degree of polymerization of 200 or more.
The adhesive gel composition according to any one of Item 5.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP60234257A JPS62215520A (en) | 1985-10-18 | 1985-10-18 | Adhesive gel composition |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP60234257A JPS62215520A (en) | 1985-10-18 | 1985-10-18 | Adhesive gel composition |
Publications (1)
Publication Number | Publication Date |
---|---|
JPS62215520A true JPS62215520A (en) | 1987-09-22 |
Family
ID=16968135
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP60234257A Pending JPS62215520A (en) | 1985-10-18 | 1985-10-18 | Adhesive gel composition |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS62215520A (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0342297A1 (en) * | 1988-05-16 | 1989-11-23 | Transphyto S.A. | Aqueous solution with low surface tension forming a wettable layer over a hydrophobic surface |
JP2007031296A (en) * | 2005-07-22 | 2007-02-08 | Hisamitsu Pharmaceut Co Inc | Hydrogel composition |
JP2008528737A (en) * | 2005-02-02 | 2008-07-31 | ノバファーム リサーチ (オーストラリア) ピーティーワイ リミテッド | Biostatic forming polymer article |
JP2018535267A (en) * | 2015-11-24 | 2018-11-29 | エルジー ハウスホールド アンド ヘルスケア リミテッド | Formulation for attachment to teeth or teeth |
-
1985
- 1985-10-18 JP JP60234257A patent/JPS62215520A/en active Pending
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0342297A1 (en) * | 1988-05-16 | 1989-11-23 | Transphyto S.A. | Aqueous solution with low surface tension forming a wettable layer over a hydrophobic surface |
JP2008528737A (en) * | 2005-02-02 | 2008-07-31 | ノバファーム リサーチ (オーストラリア) ピーティーワイ リミテッド | Biostatic forming polymer article |
JP2007031296A (en) * | 2005-07-22 | 2007-02-08 | Hisamitsu Pharmaceut Co Inc | Hydrogel composition |
JP2018535267A (en) * | 2015-11-24 | 2018-11-29 | エルジー ハウスホールド アンド ヘルスケア リミテッド | Formulation for attachment to teeth or teeth |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU679937B2 (en) | Extrudable compositions for topical or transdermal drug delivery | |
JP3249836B2 (en) | Adhesive hydrophilic gel dressing | |
US6072100A (en) | Extrudable compositions for topical or transdermal drug delivery | |
US6365664B1 (en) | Gels formed by the interaction of poly(aldehyde) with various substances | |
AU2001259601B8 (en) | Gels formed by the interaction of polyvinylpyrrolidone with chitosan derivatives | |
CA1312396C (en) | Hydrocolloid/adhesive composition | |
US5258421A (en) | Method for making tacky, hydrophilic gel dressings | |
RU2003103087A (en) | GELS FORMED BY THE INTERACTION OF POLYVINYL-PYRROLIDONE WITH CHITOSANE DERIVATIVES | |
EP0297769A1 (en) | Process for preparing a wound dressing comprising a hydrophilic acrylic adhesive layer. | |
US20020192287A1 (en) | Extrudable compositions for topical or transdermal drug delivery | |
JPH0368369A (en) | Liquid polymer bandage for dermic injury treat- ment | |
JPS62215520A (en) | Adhesive gel composition | |
US20090317451A1 (en) | Pressure-sensitive adhesive for skin surface and/or transdermal substance delivery | |
JPH066533B2 (en) | Base for hydrogel patches | |
JPH0377171B2 (en) | ||
JPH03161435A (en) | Cataplasm | |
JPS61260014A (en) | Base for hydrous patch | |
JPS6253662A (en) | Adhesive gel composition | |
JPS5846959A (en) | Production of adhesive drug | |
JPS61254519A (en) | Gelatinous medicinal pharmaceutical | |
JPS62111918A (en) | Hydrous application agent | |
JPS61172817A (en) | Medical material composition | |
JPH06128151A (en) | Base material of gel plaster containing alcohol |